The immunophenotype of healthy controls was composed of mainly six MCs: MC01 (80.3%), MC04 (6.7%), MC05 (3.6%), MC06 (3.7%), MC07 (0.19%), MC08 (4.8%) (Figure 2B), the MC01 (HLA-DR+, CD117-, CD45+, CD3+, CD34-, CD33-, CD135-, CD64-, CD7+, CD38+); MC06 (HLA-DR-, CD117-, CD45+, CD3+, CD34-, CD33-, CD135low, CD64low, CD7+, CD38+); MC07 (HLA-DRlow, CD117+, CD45+, CD3+, CD34-, CD33-, CD135+, CD64+, CD7+, CD38+), MC08 (HLA-DR-, CD117-, CD45+, CD3+, CD34-, CD33-, CD135-, CD64-, CD7-, CD38low) MCs discriminated HCs significantly against AML (Supplementary Figure 15). Here, PTPRC is linked to acute myeloid leukemia.